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Pancreatic NETs are rare tumors with multiple classification
systems. Previous classification systems included tumor size,
histologic grade, mitoses, Ki67, and metastases. The current
WHO 2010 system utilizes mitotic rate and Ki67% to assign a
grade. We compared the WHO 2004 and 2010 classification
systems in predicting mortality and metastasis.

Pancreatic neuroendocrine tumors are rare tumors of the
pancreas that are believed to develop from pluripotent ductal
cells with the ability to differentiate along neuroendocrine
lines. Approximately 80% of these tumor occur as part of
inherited disorders including Multiple Endocrine Neoplasia
type 1 (MEN1), von Hippel-Lindau disease (VHL),
neurofibromatosis 1 (NF-1) (von Recklinghausen disease),
and tuberous sclerosis complex (TSC) with the remaining
20% occurring sporadically. Pancreatic NETs comprise
approximately 5% of pancreatic neoplasms and are typically
associated with poor prognosis with a 10 year overall survival
of 45%. Histologic features of Pancreatic NETs include small
polygonal cells with moderate amount of eosinophilic
cytoplasm, salt and pepper nuclei, and positive staining with
neuroendocrine markers such as synaptophysin and
chromogranin. High grade features include increased nuclear/
cytoplasmic ration, increased mitoses, and nuclear atypia.
High grade tumors often have necrosis as well as perineural
and lymphovascular invasion.

We conducted a retrospective review of 50 patients with
Pancreatic NET diagnosed and treated at Thomas Jefferson
University Hospital between the years of 2000 and 2010.
Pathologic parameters were reviewed including tumor size,
histologic grade, Ki67%, mitoses, perineural and
lymphovascular invasion, lymph node and distant metastasis.
These parameters were used to grade each case according to
the WHO 2004 and WHO 2010 grading system. The
relationship between the WHO 2004 and WHO 2010 grading
was investigated using an exact Chi squared test. WHO grade
categorization was next explored by vital status, by the exact
method, in order to determine if there was a difference in
survivorship and metastasis by grading system. Associations
between death and categorical variables were tested using
exact methods and between death and continuous variables
by the Wilcoxon test. Survival was explored using Cox
Proportional Hazards regression (Cox).

Table 1 presents the summary of patient and disease
characteristics. Patients were mostly female(62%) and had
an average age of 60; over half had a cardiovascular
comorbidity. Figure 1 presents the relationship between WHO
grades 2004 and 2010. The WHO grades are significantly
associated with one another (p <0.001). In Table 2, both
grading systems were strongly associated with predicting
mortality; all cases of mortality were in the higher grades:
PDEC and WDEC for 2004 and G2, and G3 for 2010. Table 3
presents similar results with regard to metastases. Again
there are significant associations; however the 2010 grades
does slightly better in that metastases occur only in high
grades (G2 and G3). This is not the case for 2004 grading,
where there is a metastasis in a lower-graded patient. Table 4
presents categorical factors and their association with
mortality. Comorbidities and tumor characteristics margins
and site were not significantly different by mortality; patients
with lymphovascular or perineural invasion had significantly
higher mortality.

Pathologic parameters were used to classify 50 cases of
Pancreatic NET according to the WHO 2004 and WHO 2010
systems. The relationship between the WHO 2004 and WHO
2010 grading was investigated using an exact Chi squared
test. WHO grade categorization was next explored by vital
status, by the exact method, in order to determine if there was
a difference in survivorship and metastasis by grading
system. Associations between death and categorical
variables were tested using exact methods and between
death and continuous variables by the Wilcoxon test. Survival
was explored using Cox Proportional Hazards regression
(Cox).
The WHO grades were significantly associated with one
another (p <0.001). Both grading systems were strongly
associated with predicting mortality; all cases of mortality
were in the higher grades. The 2010 grades do slightly better
than 2004 grades in predicting metastasis as metastases
occur only in high grades (G2 and G3). Comorbidities, tumor
characteristics, margins, and site were not significantly
different by mortality; patients with lymphovascular or
perineural invasion had significantly higher mortality. Mitotic
Index was significantly different with a median of 0 in live
patients versus 15 in deceased, p <0.001. This was similarly
borne out in the survival analysis using Cox, where for every
one unit increase in Mitotic Index, there was about a one third
increase in the hazard of death (p = 0.001). There was no
significant difference in survival by tumor size, comorbidities,
or margins. Our data show that the WHO 2010 grading
system is strongly associated with predicting mortality and
performs better in predicting liver metastasis than the 2004
grading system.

Currently, these tumors are classified according to the World
Health Organization 2010 grading system although there have
been several revisions of this system in recent years. The
2010 classification system uses only Ki67 percentage and
mitoses in grading Pancreatic NETs. Grade 1 tumors have
mitotic count of <2 mitoses per 10 high-power fields (hpf) and
<3% Ki67 index; Grade 2 tumors have mitotic count of 2 to 20
mitoses per10 hpf or 3% to 20% Ki67 index; and Grade 3
tumors have mitotic count of >20 mitoses per10 hpf or >20%
Ki67 index.
Previous classifications included multiple pathologic and
clinical parameters such as tumor size, histologic grade,
mitoses, Ki67%, perineural/vascular invasion, and presence
of metastasis. Accurate grading of Pancreatic NETs is critical
to determine prognosis as well as determining follow-up
monitoring and treatment. Our study looked at 50 resected
Pancreatic NETs at Thomas Jefferson University to determine
if the WHO 2010 system accurately classified tumors with
respect to metastasis and survival. Future studies will
investigate molecular markers that correlate with tumor grade
and mortality.
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Tumor size did not differ by mortality with a median
[minimum, maximum] in live patients of 2.4 [0.08, 12] versus
3.45 [2.7, 7.6], p = 0.116, however mitotic Index was
significantly different with a median [minimum, maximum] of 0
[0, 10] in live patients versus 15 [2, 30] in deceased, p <0.001.
This was similarly borne out in the survival analysis using Cox
Proportional Hazards regression (see Table 5), where for
every one unit increase in Mitotic Index, there was about a
one third increase in the hazard of death (p = 0.001). There
was no significant difference in survival by tumor size,
comorbidities, or margins.

CONCLUSION
The WHO 2010 grading system is strongly associated with
predicting mortality and performs better in predicting
liver metastasis than the 2004 grading system. Future studies
include determining which tumors responded best to
chemotherapy following surgery as well as finding molecular
markers that correlate with tumor grade and prognosis.
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